Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen for Social Function in Fragile X Syndrome
NCT01282268Phase 3Completed
- Sponsor
- Seaside Therapeutics
- Start
- May 2011
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fragile X syndrome (FXS) comparing Arbaclofen with Placebo (2 arms). Primary endpoint: Aberrant Behavior Checklist - FXS Social Avoidance Subscale at 8 weeks. Started May 2011; status: completed.
02
Drugs
arbaclofen
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01282268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01282268.